Matching cancer patients with targeted therapies based on their molecular profiles
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials
This study is testing whether matching cancer patients with targeted treatments based on their unique genetic profiles can improve their chances of getting better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Bergonié Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 7 sites (Bayonne and 6 other locations) |
| Trial ID | NCT02534649 on ClinicalTrials.gov |
What this trial studies
This study aims to personalize cancer treatment by identifying actionable molecular alterations in patients with advanced solid tumors or hematological malignancies. Using next-generation sequencing and immunological profiling, the study will analyze tumor and blood samples to create a comprehensive molecular profile for each patient. This profile will help clinicians match patients to specific early phase clinical trials that are most likely to benefit them based on their unique genetic characteristics.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with advanced solid tumors or hematological malignancies.
Not a fit: Patients who are pregnant, breastfeeding, or have been previously enrolled in this study may not receive any benefit.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and tailored cancer treatments for patients with advanced disease.
How similar studies have performed: Other studies utilizing personalized medicine approaches have shown promise, indicating potential success for this novel methodology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years, 2. Histology: solid malignant tumor or hematological malignancy, 3. Deleted MSA9 4. Deleted MSA9, 5. Deleted MSA9, 6. Deleted MSA9, 7. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code), 8. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Deleted MSA9 2. Deleted MSA9 3. Deleted MSA9 4. Deleted MSA9 5. Deleted MSA9 6. Deleted MSA9 7. Deleted MSA9 8. Deleted MSA9 9. Individuals deprived of liberty or placed under guardianship 10. Pregnant or breast feeding women, 11. Previous enrolment in the present study.
Where this trial is running
Bayonne and 6 other locations
- Centre Hospitalier de la Côte Basque — Bayonne, France (Recruiting)
- Clinique Tivoli-Ducos — Bordeaux, France (Recruiting)
- Institut Bergonie — Bordeaux, France (Recruiting)
- Polyclinique Bordeaux Nord Aquitaine — Bordeaux, France (Recruiting)
- Centre Hospitalier de Pau — Pau, France (Not_yet_recruiting)
- Clinique Marzet — Pau, France (Recruiting)
- Centre Eugène Marquis — Rennes, France (Active_not_recruiting)
Study contacts
- Study coordinator: Antoine ITALIANO, MD, PhD
- Email: a.italiano@bordeaux.unicancer.fr
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.